Evidence map›Paper›PMID 30646354›Full record

ArticleJAMA network open2018

Association of the Haptoglobin Gene Polymorphism With Cognitive Function and Decline in Elderly African American Adults With Type 2 Diabetes: Findings From the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Study.

Michal S Beeri, Hung-Mo Lin, Mary Sano, Ramit Ravona-Springer, Xiaoyu Liu, Barbara B Bendlin, Carey E Gleason, Elizabeth Guerrero-Berroa, Laili Soleimani, Lenore J Launer and 4 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Haptoglobin as a Biomarker.Biochemistry (Moscow) Supplement. Series B, Biomedical chemistry · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Michal S BeeriDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Hung-Mo LinDepartment of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York.
Mary SanoDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Ramit Ravona-SpringerThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel.
Xiaoyu LiuDepartment of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York.
Barbara B BendlinDivision of Geriatrics and Gerontology, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison.
Carey E GleasonDivision of Geriatrics and Gerontology, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison.
Elizabeth Guerrero-BerroaDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Laili SoleimaniDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Lenore J LaunerLaboratory of Epidemiology and Population Science, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.
Scott Ehrenbergcurrently a student at Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Orit LacheDepartment of Medicine, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Yaakov K SeligmanDepartment of Medicine, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Andrew P LevyDepartment of Medicine, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Icahn School of Medicine at Mount Sinai · USTechnion – Israel Institute of Technology · ILUniversity of Wisconsin–Madison · USNational Institutes of Health · USSheba Medical Center · IL

Funding

Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI SAGER, MARK · 2009 to 2018
$16.2M
African Americans Fighting Alzheimer’s in Midlife (AA-FAIM)R01AG054059 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CAREY E GLEASON · 2016 to 2026
$15.3M
Inflammation, long-term diabetes characteristics, and cognitive declineR01AG034087 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHNAIDER BEERI, MICHAL · 2009 to 2014
$3.7M
Diabetes and the brainZIAAG007420 · NIA · NATIONAL INSTITUTE ON AGING · PI LAUNER, LENORE J · 2009 to 2021
$2.1M
NIA NIH HHS P50 AG033514NIA NIH HHS R01 AG034087NIA NIH HHS R01 AG054059
6 · The paper itself

Abstract

Importance: African American individuals have higher dementia risk than individuals of white race/ethnicity. They also have higher rates of type 2 diabetes, which may contribute to this elevated risk. This study examined the association of the following 2 classes of alleles at the haptoglobin (Hp) locus that are associated with poor cognition, cardiovascular disease, and mortality: Hp 1-1 (associated with poor cognition and cerebrovascular disease) and Hp 2-1 and Hp 2-2 (associated with greater risk of myocardial infarction and mortality). An additional polymorphism in the promoter region of the Hp 2 allele, restricted to individuals of African descent, yields a fourth genotype, Hp 2-1m. African American adults have a higher prevalence of Hp 1-1 (approximately 30%) compared with individuals of white race/ethnicity (approximately 14%), but the potential role of the Hp genotype in cognition among elderly African American individuals with type 2 diabetes is unknown. Objective: To assess the association of the Hp genotypes with cognitive function and decline in elderly African American adults with type 2 diabetes. Design, Setting, and Participants: This cohort study used publicly available data and specimens from the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) study to investigate the association of the Hp genotypes with cognitive function and decline in 466 elderly African American participants with type 2 diabetes. The hypothesis was that the Hp 1-1 genotype compared with the other genotypes would be associated with more cognitive impairment and faster cognitive decline in elderly African American adults with type 2 diabetes. The initial ACCORD trial was performed from October 28, 1999, to September 15, 2014. This was a multicenter clinical study performed in an academic setting. Exposures: The Hp genotypes were determined from serum samples by polyacrylamide gel electrophoresis and by enzyme-linked immunosorbent assay. Main Outcomes and Measures: The Mini-Mental State Examination (MMSE) was used to measure cognitive function and change after 40 months. The MMSE score ranges from 0 to 30 points; higher scores represent better cognition. Associations were examined with analysis of covariance and linear regression, adjusting for age, sex, education, baseline glycated hemoglobin level, systolic blood pressure, diastolic blood pressure, cholesterol level, creatinine level, and treatment arm (intensive vs standard). The cognitive change model adjusted also for the baseline MMSE score. Results: Among 466 African American study participants (mean [SD] age, 62.3 [5.7] years), 64.8% were women, and the genotype prevalences were 29.4% (n = 137) for Hp 1-1, 36.1% (n = 168) for Hp 2-1, 10.9% (n = 51) for Hp 2-1m, and 23.6% (n = 110) for Hp 2-2. The groups differed in their baseline MMSE scores (P = .006): Hp 1-1 had the lowest MMSE score (mean [SE], 25.68 [0.23]), and Hp 2-1m had the highest MMSE score (mean [SE], 27.15 [0.36]). Using the least squares method, the 40-month decline was significant for Hp 1-1 (mean [SE], -0.41 [0.19]; P = .04) and for Hp 2-2 (mean [SE], -0.68 [0.21]; P = .001). However, the overall comparison across the 4 groups did not reach statistical significance for the fully adjusted model. The interaction of age with the Hp 1-1 genotype on MMSE score decline estimate per year change was significant (mean [SE], -0.87 [0.37]; P = .005), whereas it was not significant for Hp 2-1 (mean [SE], 0.06 [0.37]; P = .85), Hp 2-1m (mean [SE], -0.06 [0.51]; P = .89), and Hp 2-2 (mean [SE], -0.44 [0.41]; P = .29), indicating that cognitive decline in Hp 1-1 carriers was accentuated in older ages, whereas it was not significant for the other Hp genotypes. Conclusions and Relevance: In this study, the Hp 1-1 genotype, which is 2-fold (approximately 30%) more prevalent among African American individuals than among individuals of white race/ethnicity, was associated with poorer cognitive function and greater cognitive decline than the other Hp genotypes. The Hp gene polymorphism may explain the elevated dementia risk in African American adults. The neuropathological substrates and mechanisms for these associations merit further investigation.

Indexed as

CognitionGenotypePolymorphism, GeneticAgedAge FactorsAllelesBlack or African AmericanCardiovascular DiseasesCognition DisordersCohort StudiesDementiaDiabetes Mellitus, Type 2Disease ProgressionFemaleHaptoglobinsHumansHaptoglobins

Identifiers

PMID30646354
PMCPMC6324406
OpenAlexW2899948238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.